Ascorbate

别名: Ascorbate Vitamin C sodium Sodium Ascorbate 抗坏血酸钠;维生素 C 钠;L-抗坏血酸钠;维生素C钠盐;维他命C钠;抗坏血酸钠盐;抗坏血酸钠盐(维生素C钠);L-抗坏血酸钠盐;维生素C缓冲液(中性维生素C);缓冲液(中性维生素C);VC抗坏血酸钠;抗坏血酸钠 GMP;(+)-L-抗坏血酸钠; L-抗坏血酸钠 标准品;Sodium ascorbate 抗坏血酸钠;Sodium L-Ascorbate L-抗坏血酸钠;VC钠;VC钠( 抗坏血酸钠);VC钠(抗坏血酸钠);抗坏血酸钠 EP标准品;抗坏血酸钠 USP标准品;抗坏血酸钠 vc钠;抗坏血酸钠(维生素C钠);抗坏血酸钠,维生素C钠;抗坏血酸钠钠;食品级VC钠 (L-抗坏血酸钠);维C钠;维生素 C 钠 (L-抗坏血酸钠);维生素C钠 VC钠;维生素C钠(抗坏血酸钠);抗坏血酸钠(维生素C钠盐)
目录号: V8179 纯度: ≥98%
L-抗坏血酸钠盐(抗坏血酸钠)是一种电子供体,是一种内源性抗氧化剂。
Ascorbate CAS号: 134-03-2
产品类别: New1
产品仅用于科学研究,不针对患者销售
规格 价格 库存 数量
500mg
1g
Other Sizes

Other Forms of Ascorbate:

  • L-Ascorbic acid, 2,6-dibutanoate (2,6-Di-O-butyryl-L-ascorbic Acid)
  • 6-O-Stearoyl-L-ascorbic acid (Vitamin C stearate; Ascorbic acid 6-stearate; Ascorbyl stearate)
  • 5,6-O-Isopropylidene-L-ascorbic acid (L-Ascorbic acid 5,6-acetonide)
  • L-Ascorbic acid calcium dihydrate (L-Ascorbate calcium dihydrate; Vitamin C calcium dihydrate)
  • Glyceryl ascorbate (2-O-(2,3-Dihydroxypropyl)-L-ascorbic Acid)
  • 维生素C
点击了解更多
InvivoChem产品被CNS等顶刊论文引用
纯度/质量控制文件

纯度: ≥98%

产品描述
L-抗坏血酸钠盐(抗坏血酸钠)是一种电子供体,是一种内源性抗氧化剂。 L-抗坏血酸钠盐选择性抑制 Cav3.2 通道,IC50 为 6.5 μM。 L-抗坏血酸钠盐也是胶原蛋白沉积促进剂和弹性生成抑制剂。
生物活性&实验参考方法
体外研究 (In Vitro)
B16F10细胞条件培养基的活性成分相对分子质量小于5,000,可强烈减少L-抗坏血酸钠(10 mM)诱导的细胞凋亡[4]。
体内研究 (In Vivo)
与未用L-抗坏血酸钠(Sodium L-ascorbate)治疗的Tg大鼠相比,用L-抗坏血酸钠(15.4%)治疗的Tg大鼠的癌症发病率更高(29.6%)。即使没有 L-抗坏血酸钠盐治疗,转基因大鼠也会出现多种器官癌症 [5]。 PEITC 治疗 12 周后,所有动物均出现单纯性增生和乳头状或结节性 (PN) 增生;然而,无论是否进行钠盐(L-抗坏血酸)治疗,大多数病变都会在 48 周后消退。到第 48 周,即经过 24 周的 PEITC 治疗后,少数病例中相同的病变已进展为不典型增生和癌症;然而,大鼠单纯性增生和PN增生是L-抗坏血酸钠盐治疗显示出增强作用的唯一情况。 [6]。
药代性质 (ADME/PK)
Absorption, Distribution and Excretion
Ascorbic acid, the reduced form of vitamin C, functions as a potent antioxidant as well as in cell differentiation. Ascorbate is taken up by mammalian cells through the specific sodium/ascorbate co-transporters SVCT1 and SVCT2. Although skeletal muscle contains about 50% of the whole-body vitamin C, the expression of SVCT transporters has not been clearly addressed in this tissue. ... This work ... analyzed the expression pattern of SVCT2 during embryonic myogenesis using the chick as model system. ... Immunohistochemical analyses showed that SVCT2 is preferentially expressed by type I slow-twitch muscle fibers throughout chick myogenesis as well as in post-natal skeletal muscles of several species, including human...
Humans use two sodium-ascorbate cotransporters (hSVCT1 and hSVCT2) for transporting the dietary essential micronutrient ascorbic acid, the reduced and active form of vitamin C. Although the human liver plays a pivotal role in regulating and maintaining vitamin C homeostasis, vitamin C transport physiology and regulation of the hSVCT systems in this organ have not been well defined. Thus, this research used a human hepatic cell line (HepG2), confirming certain results with primary human hepatocytes and determined the initial rate of ascorbic acid uptake to be Na(+) gradient, pH dependent, and saturable as a function of concentration over low and high micromolar ranges. Additionally, hSVCT2 protein and mRNA are expressed at higher levels in HepG2 cells and native human liver, and the cloned hSVCT2 promoter has more activity in HepG2 cells. Results using short interfering RNA suggest that in HepG2 cells, decreasing hSVCT2 message levels reduces the overall ascorbic acid uptake process more than decreasing hSVCT1 message levels. Activation of PKC intracellular regulatory pathways caused a downregulation in ascorbic acid uptake not mediated by a single predicted PKC-specific amino acid phosphorylation site in hSVCT1 or hSVCT2. However, PKC activation causes internalization of hSVCT1 but not hSVCT2. Examination of other intracellular regulatory pathways on ascorbic acid uptake determined that regulation also potentially occurs by PKA, PTK, and Ca(2+)/calmodulin, but not by nitric oxide-dependent pathways...
Metabolism / Metabolites
... Adrenal cortex is closely associated with ascorbate metabolism ... Hydrocortisone was reported ... to stimulate synthesis of ascorbate from gluconolactone, but deoxycorticosterone or aldosterone caused ... increase in ascorbate excretion in normal or adrenalectomized rats...
毒性/毒理 (Toxicokinetics/TK)
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
Vitamin C is a normal component of human milk and is a key milk antioxidant. The recommended vitamin C intake in lactating women is 120 mg daily, and for infants aged 6 months or less is 40 mg daily. High daily doses up to 1000 mg increase milk levels, but not enough to cause a health concern for the breastfed infant and is not a reason to discontinue breastfeeding. Nursing mothers may need to supplement their diet to achieve the recommended intake or to correct a known deficiency. Maternal doses of vitamin C in prenatal vitamins at or near the recommended intake do not alter milk levels.
Freezing (-20 degrees C) freshly expressed mature milk from hospitalized mothers of term and preterm infants does not change milk vitamin C levels for at least 3 months of freezer storage. After 6 to 12 months of freezing (-20 degrees C), vitamin C levels can decrease by 15 to 30%. Storage at -80 degrees C preserves vitamin C levels for up to 8 months, with 15% loss by 12 months.
◉ Effects in Breastfed Infants
Sixty healthy lactating women between 1 and 6 months postpartum exclusively breastfeeding their infants were given vitamin C 500 mg plus vitamin E 100 IU once daily for 30 days, or no supplementation. Infants of supplemented mothers had increased biochemical markers of antioxidant activity in their urine. Clinical outcomes were not reported.
Eighteen preterm infants, seven of whom were less than 32 weeks gestational age, who were fed pooled, Holder-pasteurized donor milk beginning during the first three days of life had their average blood plasma ascorbic acid concentrations decrease from 15.5 mg/L at birth to 5.4 mg/L by 1 week of age, and to 4.1 mg/L by 3 weeks of age. The authors described the 1- and 3-week levels as subtherapeutic (<6 mg/L) and indicative of inadequate intake, potentially jeopardizing postnatal growth potential. Although this study was conducted before advances in the provision of parenteral nutrition and enteral milk fortification for preterm infants, contemporary studies suggest that inadequate vitamin C intake from pooled, pasteurized donor milk may be a potential health problem for preterm infants receiving donor milk.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Interactions
Tissues exposed to Na ascorbate responded more vigorously than untreated muscles when graded concentrations of calcium chloride added to bathing solution minus Ca2+ ions but with acetylcholine.
The effects of sodium ascorbate with or without Vitamin K3 was studied in vitro using cultured human neoplastic cell lines MCF-7 (breast carcinoma), KB (oral epidermal carcinoma), and AN3-CA (endometrial adenocarcinoma) at concentrations of 0.198 ug/mL to 1.98 mg/mL. Culture media without sodium ascorbate and the vitamin were used as a control. At 50%confluence, different combinations of sodium ascorbate and Vitamin K3 were added to the cultures for a 1 hr incubation. DNA determinations were made. Sodium Ascorbate supplemented media had a growth inhibiting action only at high concentrations (5 x 10+3 mol/L). Combined administration demonstrated a synergisitic inhibition of cell growth at 10 to 50 times lower concentrations. These results are for all three cell types ...
Sodium ascorbate and/or sodium nitrite /was administered/ for 6 months to male and female Wistar rats (5 rats/group). The control group was fed a basal diet and water only. Treated groups were administered the following: 0.075%, 0.15%, or 0.3% sodium nitrite dissolved in water; 1%, 2%, or 4% sodium ascorbate; or a combination with both chemicals at low + low, middle + middle, and high + high doses. Body weight gain was significantly decreased in the combined-high dose group. Significant decreases of serum total protein, increase of BUN (blood urea nitrogen) and relative kidney weight were also found in the combined-high dose group. Histopathological examination showed moderate or severe squamous cell hyperplasia of the forestomach in the combined-high dose group and slight hyperplasia in the combined-middle dose group. No differences were seen between the sexes. The minimum toxic dose was 0.15% sodium nitrite+2% sodium ascorbate ...
参考文献

[1]. Sodium L-ascorbate enhances elastic fibers deposition by fibroblasts from normal and pathologic human skin. J Dermatol Sci. 2014 Sep;75(3):173-82.

[2]. Sodium L-ascorbate enhances elastic fibers deposition by fibroblasts from normal and pathologic human skin. J Dermatol Sci. 2014 Sep;75(3):173-82.

[3]. Molecular mechanisms of subtype-specific inhibition of neuronal T-type calcium channels by ascorbate. J Neurosci. 2007 Nov 14;27(46):12577-83.

[4]. Mouse melanoma cell line B16F10-derived conditioned medium inhibits sodium L-ascorbate-induced B16F10 cell apoptosis. Nan Fang Yi Ke Da Xue Xue Bao. 2012 Feb;32(2):146-50.

[5]. Lack of urinary bladder carcinogenicity of sodium L-ascorbate in human c-Ha-ras proto-oncogene transgenic rats. Toxicol Pathol. 2005;33(7):764-7.

[6]. Limited tumor-initiating activity of phenylethyl isothiocyanate by promotion with sodium L-ascorbate in a rat two-stage urinary bladder carcinogenesis model. Cancer Lett. 2005 Mar 10;219(2):147-53.

其他信息
Minute crystals or white powder. pH of aqueous solutions 5.6 to 7.0 or even higher (a 10% solution, made from a commercial grade, may have a pH of 7.4 to 7.7). (NTP, 1992)
Sodium ascorbate is an organic sodium salt resulting from the replacement of the proton from the 3-hydroxy group of ascorbic acid by a sodium ion. It has a role as a food antioxidant, a flour treatment agent, a coenzyme, a plant metabolite, a human metabolite, a Daphnia magna metabolite and a reducing agent. It is an organic sodium salt and a vitamin C. It contains a L-ascorbate.
A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.
See also: Ascorbic Acid (has active moiety) ... View More ...
Mechanism of Action
Mechanism of action of ascorbate is a superoxide radical scavenger.
... Sodium ascorbate decreases cellular iron uptake by melanoma cells in a dose- and time-dependent fashion, indicating that intracellular iron levels may be a critical factor in sodium ascorbate-induced apoptosis. Indeed, sodium ascorbate-induced apoptosis is enhanced by the iron chelator, desferrioxamine (DFO) while it is inhibited by the iron donor, ferric ammonium citrate (FAC). Moreover, the inhibitory effects of sodium ascorbate on intracellular iron levels are blocked by addition of transferrin, suggesting that transferrin receptor (TfR) dependent pathway of iron uptake may be regulated by sodium ascorbate. Cells exposed to sodium ascorbate demonstrated down-regulation of TfR expression and this precedes sodium ascorbate-induced apoptosis. Taken together, sodium ascorbate-mediated apoptosis appears to be initiated by a reduction of TfR expression, resulting in a down-regulation of iron uptake followed by an induction of apoptosis...
Humans use two sodium-ascorbate cotransporters (hSVCT1 and hSVCT2) for transporting the dietary essential micronutrient ascorbic acid, the reduced and active form of vitamin C. Although the human liver plays a pivotal role in regulating and maintaining vitamin C homeostasis, vitamin C transport physiology and regulation of the hSVCT systems in this organ have not been well defined. Thus, this research used a human hepatic cell line (HepG2), confirming certain results with primary human hepatocytes and determined the initial rate of ascorbic acid uptake to be Na(+) gradient, pH dependent, and saturable as a function of concentration over low and high micromolar ranges. Additionally, hSVCT2 protein and mRNA are expressed at higher levels in HepG2 cells and native human liver, and the cloned hSVCT2 promoter has more activity in HepG2 cells. Results using short interfering RNA suggest that in HepG2 cells, decreasing hSVCT2 message levels reduces the overall ascorbic acid uptake process more than decreasing hSVCT1 message levels. Activation of PKC intracellular regulatory pathways caused a downregulation in ascorbic acid uptake not mediated by a single predicted PKC-specific amino acid phosphorylation site in hSVCT1 or hSVCT2. However, PKC activation causes internalization of hSVCT1 but not hSVCT2. Examination of other intracellular regulatory pathways on ascorbic acid uptake determined that regulation also potentially occurs by PKA, PTK, and Ca(2+)/calmodulin, but not by nitric oxide-dependent pathways...
Therapeutic Uses
Antioxidants; Free Radical Scavengers
Ascorbic acid and calcium and sodium ascorbates are used as antoxidants in pharmaceutical manufacturing and in the food industry.
In 20 patients in acute asthmatic crisis, 16 recovered promptly after receiving 6 g sodium ascorbate iv. Chronic oral treatment (0.6-1 g/day/60 days) with Na ascorbate prevented asthmatic symptoms in 18/25 asthmatic patients.
8 patients with hyphema were treated with iv glycerin in combination with sodium ascorbate. The results showed that glycerol in combination with sodium ascorbate diminished the hemorrhage in eye within 12-24 hr.
For more Therapeutic Uses (Complete) data for Sodium ascorbate (6 total), please visit the HSDB record page.
Drug Warnings
Each gram of sodium ascorbate contains approximately 5 mEq of sodium; this should be considered when the drug is used in patients on salt-restricted diets.
*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性
化学信息 & 存储运输条件
分子式
C6H7NAO6
分子量
198.11
精确质量
198.014
CAS号
134-03-2
相关CAS号
L-Ascorbic acid;50-81-7;L-Ascorbic acid (GMP Like);50-81-7
PubChem CID
23667548
外观&性状
Off-white to light yellow solid powder
密度
1.799 g/cm3
沸点
552.7ºC at 760 mmHg
熔点
220 °C (dec.)(lit.)
闪点
238.2ºC
蒸汽压
1.62E-14mmHg at 25°C
折射率
105.5 ° (C=10, H2O)
tPSA
110.05
氢键供体(HBD)数目
3
氢键受体(HBA)数目
6
可旋转键数目(RBC)
2
重原子数目
13
分子复杂度/Complexity
237
定义原子立体中心数目
2
SMILES
[Na+].O1C(C(=C([C@@]1([H])[C@]([H])(C([H])([H])O[H])O[H])[O-])O[H])=O
InChi Key
PPASLZSBLFJQEF-RXSVEWSESA-M
InChi Code
InChI=1S/C6H8O6.Na/c7-1-2(8)5-3(9)4(10)6(11)12-5;/h2,5,7-10H,1H2;/q;+1/p-1/t2-,5+;/m0./s1
化学名
sodium;(2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2H-furan-3-olate
别名
Ascorbate Vitamin C sodium Sodium Ascorbate
HS Tariff Code
2934.99.9001
存储方式

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

注意: 请将本产品存放在密封且受保护的环境中(例如氮气保护),避免吸湿/受潮和光照。
运输条件
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
溶解度数据
溶解度 (体外实验)
H2O : ~100 mg/mL (~504.77 mM)
DMSO : ~1 mg/mL (~5.05 mM)
溶解度 (体内实验)
配方 1 中的溶解度: 50 mg/mL (252.39 mM) in PBS (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液; 超声助溶。

请根据您的实验动物和给药方式选择适当的溶解配方/方案:
1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL;

3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果,工作液请现配现用!
6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。
制备储备液 1 mg 5 mg 10 mg
1 mM 5.0477 mL 25.2385 mL 50.4770 mL
5 mM 1.0095 mL 5.0477 mL 10.0954 mL
10 mM 0.5048 mL 2.5239 mL 5.0477 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;

3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);

4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。

计算器

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度,具体如下:

  • 计算制备已知体积和浓度的溶液所需的化合物的质量
  • 计算将已知质量的化合物溶解到所需浓度所需的溶液体积
  • 计算特定体积中已知质量的化合物产生的溶液的浓度
使用摩尔浓度计算器计算摩尔浓度的示例如下所示:
假如化合物的分子量为350.26 g/mol,在5mL DMSO中制备10mM储备液所需的化合物的质量是多少?
  • 在分子量(MW)框中输入350.26
  • 在“浓度”框中输入10,然后选择正确的单位(mM)
  • 在“体积”框中输入5,然后选择正确的单位(mL)
  • 单击“计算”按钮
  • 答案17.513 mg出现在“质量”框中。以类似的方式,您可以计算体积和浓度。

稀释计算器可计算如何稀释已知浓度的储备液。例如,可以输入C1、C2和V2来计算V1,具体如下:

制备25毫升25μM溶液需要多少体积的10 mM储备溶液?
使用方程式C1V1=C2V2,其中C1=10mM,C2=25μM,V2=25 ml,V1未知:
  • 在C1框中输入10,然后选择正确的单位(mM)
  • 在C2框中输入25,然后选择正确的单位(μM)
  • 在V2框中输入25,然后选择正确的单位(mL)
  • 单击“计算”按钮
  • 答案62.5μL(0.1 ml)出现在V1框中
g/mol

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成,具体如下:

注:化学分子式大小写敏感:C12H18N3O4  c12h18n3o4
计算化合物摩尔质量(分子量)的说明:
  • 要计算化合物的分子量 (摩尔质量),请输入化学/分子式,然后单击“计算”按钮。
分子质量、分子量、摩尔质量和摩尔量的定义:
  • 分子质量(或分子量)是一种物质的一个分子的质量,用统一的原子质量单位(u)表示。(1u等于碳-12中一个原子质量的1/12)
  • 摩尔质量(摩尔重量)是一摩尔物质的质量,以g/mol表示。
/

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

  • 输入试剂的质量、所需的配液浓度以及正确的单位
  • 单击“计算”按钮
  • 答案显示在体积框中
动物体内实验配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶/难溶于水的化合物),不同的产品和批次配方组成不同,如对配方有疑问,可先联系我们提供正确的体内实验配方。此外,请注意这只是一个配方计算器,而不是特定产品的确切配方。
+
+
+

计算结果:

工作液浓度 mg/mL;

DMSO母液配制方法 mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。

体内配方配制方法μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。

(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
            (2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息
NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03508726 COMPLETEDWITH RESULTS Drug: Ascorbate Soft Tissue Sarcoma Mohammed Milhem 2019-06-27 Phase 1
Phase 2
NCT04877587 WITHDRAWN Drug: Ascorbate
Drug: Gemcitabine
Bone Sarcoma
Metastatic Bone Sarcoma
Metastatic Soft-tissue Sarcoma
Soft Tissue Sarcoma
David Dickens 2023-01 Early Phase 1
NCT02420314 COMPLETEDWITH RESULTS Drug: Paclitaxel
Drug: Carboplatin
Drug: Ascorbic Acid
Carcinoma, Non-Small-Cell Lung Joseph J. Cullen, MD, FACS 2015-04 Phase 2
NCT06433791 NOT YET RECRUITING Drug: Ascorbate-Meglumine Safety LadeRx LLC 2024-06-17 Phase 1
NCT04634227 RECRUITING Drug: Ascorbate Bone Sarcoma
Metastatic Bone Tumor
Sarcoma
Soft Tissue Sarcoma
Unresectable Soft Tissue Sarcoma
Mohammed Milhem, MBBS 2020-11-24 Early Phase 1
生物数据图片
  • Ascorbate inhibition of rat DRG T-currents. A, Time course showing the effects of various ascorbate concentrations on T-currents from an acutely dissociated DRG neuron. T-currents were evoked by 175 ms steps from −90 to −40 mV every 10 s. B, Concentration–response curve for inhibition of DRG T-currents by ascorbate. Average data were fit with Equation 1 to generate the curve: IC50, 6.5 ± 3.9 μm; h, 0.56 ± 0.12; maximal inhibition, 70.2 ± 2.1%; (n = 4–9). C, T-currents evoked from a DRG neuron by steps from −90 to −80 through −20 mV (Δ5 mV), before and during exposure to ascorbate. D, Averaged effects of ascorbate on DRG T-currents evoked by steps from −90 mV to the indicated test potentials (n = 8). E, Averaged effects of ascorbate on the kinetics of DRG T-current activation calculated as 10–90% rise time from IV data (n = 8). F, Averaged effects of ascorbate on the kinetics of DRG T-current inactivation calculated from single exponential fits of IV data (n = 8). G, Raw traces and average effects of ascorbate on voltage-dependent activation of DRG T-currents: control, V50, −49.0 ± 0.3; k, 6.2 ± 0.2; ascorbate, V50 −44.1 ± 0.9; k, 11.9 ± 0.8 (n = 6). Data were calculated from isochronal tail currents evoked by 10 ms steps from −90 to −80 through 20 mV (Δ5 mV), where the amplitude of the tail current is a measure of the conductance activated during the preceding pulse. Average data were fit with Equation 2 to generate curves. [3]. Michael T Nelson, et al. Molecular mechanisms of subtype-specific inhibition of neuronal T-type calcium channels by ascorbate. J Neurosci. 2007 Nov 14;27(46):12577-83.
  • Ascorbate inhibits Cav3.2, but not Cav3.1 or Cav3.3 T-currents in both native thalamic and recombinant HEK293 cells. A–C, Time courses and raw traces showing the differential effects of ascorbate on T-currents from representative nRT, LD, and VB thalamic neurons. D–F, Raw traces showing the differential effects of ascorbate on T-currents from recombinant Cav3.1, Cav3.2, and Cav3.3 channels expressed in HEK293 cells. G, Averaged effects of ascorbate on T-currents in thalamic nuclei expressed as a percentage of control: nRT, 72.6 ± 2.9%; p < 0.01; LD, 97.8 ± 1.4%; VB, 98.0 ± 1.6% (n = 3–9). H, Averaged effects of ascorbate on recombinant T-currents expressed as a percentage of control: Cav3.1, 98.8 ± 1.1%; Cav3.2, 30.7 ± 5.5%; p < 0.01; Cav3.3, 97.4 ± 5.6% (n = 5–8). I, Concentration–response curve for inhibition of recombinant Cav3.2 currents by ascorbate. Average data were fit with Equation 1 to generate the curve: IC50, 9.75 ± 0.01 nm; h, 0.60 ± 0.05; maximal inhibition, 69.9 ± 1.2% (n = 4–7) for the human clone and IC50, 25.10 ± 0.01 nm; h, 0.45 ± 0.08; maximal inhibition, 75.1 ± 4.0% (n = 4–7) for the rat clone. *p < 0.01.[3]. Michael T Nelson, et al. Molecular mechanisms of subtype-specific inhibition of neuronal T-type calcium channels by ascorbate. J Neurosci. 2007 Nov 14;27(46):12577-83.
  • Ascorbate inhibition of recombinant Cav3.2 T-currents in HEK293 cells. A, Currents evoked from an HEK293 cell expressing human Cav3.2 by steps from −90 to −80 through −25 mV (Δ5 mV), before and during exposure to ascorbate. B, Averaged effects of ascorbate on Cav3.2 currents evoked by steps from −90 to −80 through 25 mV (n = 8). C, Averaged effects of ascorbate on the kinetics of Cav3.2 current activation calculated as 10–90% rise time from IV data (n = 8). D, Averaged effects of ascorbate on the kinetics of Cav3.2 current inactivation calculated from single exponential fits of IV data (n = 8). E, Average effects of ascorbate on voltage-dependent activation of Cav3.2 current: control, V50, −49.3 ± 0.3; k, 5.0 ± 0.3; ascorbate, V50, −42.5 ± 1.2; k, 10.6 ± 1.3 (n = 4). Data were calculated from isochronal tail currents evoked by 10 ms steps from −90 to −80 through 0 mV (Δ5 mV), where the amplitude of the tail current is a measure of the conductance activated during the preceding pulse. Average data were fit with Equation 2 to generate curves. F, Average effects of ascorbate on steady-state inactivation of Cav3.2 current: control, V50, −70.0 ± 0.4; k, 6.9 ± 0.4; ascorbate, V50, −76.0 ± 0.4; k, 7.2 ± 1.6 (n = 5). Currents were recorded at −30 mV after prepulses lasting 3.5 s to potentials from −110 to −45 mV. Average data were fit with Equation 3 to generate curves.[3]. Michael T Nelson, et al. Molecular mechanisms of subtype-specific inhibition of neuronal T-type calcium channels by ascorbate. J Neurosci. 2007 Nov 14;27(46):12577-83.
相关产品
联系我们